PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Etifoxine→

Etifoxine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
21715-46-8
Molecular formula
C17H17ClN2O
Molecular weight
300.8 g/mol
Drug class
Non-benzodiazepine anxiolyticbenzoxazine derivative and GABAergic modulator
Mechanism of action
Enhances GABA-A receptor-mediated inhibitory neurotransmission by two complementary actions: direct interaction with beta-2/beta-3 receptor subunits and indirect modulation through the mitochondrial translocator protein (TSPO), promoting neurosteroid synthesis that positively modulates GABA-A receptors.
Indications / reported uses
  • Short-term treatment of anxiety symptoms or adjustment disorders with anxiety in countries where etifoxine is authorised; indication, treatment duration and safety restrictions are product- and jurisdiction-specific

Sources: Peer-reviewed review — An update on the anxiolytic and neuroprotective properties of etifoxine · Peer-reviewed clinical review — Etifoxine for pain patients with anxiety · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Etifoxine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Etifoxine Permitted Daily Exposure (PDE) report (the Etifoxine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Etifoxine Occupational Exposure Limit (OEL) report (the Etifoxine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.